Fair Value Measurement - Additional Information (Detail)	1 Months Ended	3 Months Ended	6 Months Ended
Mar. 31, 2013 Novozymes Biopharma Sweden Ab Earn Out Payment EUR (€)	Jun. 30, 2013 Novozymes Biopharma Sweden Ab Earn Out Payment EUR (€)	Jun. 30, 2013 Novozymes Biopharma Sweden Ab Earn Out Payment EUR (€)	Jun. 30, 2013 Bio Flash Partners Limited Liability Company Minimum USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business acquisition, contingent payment	€ 1,000,000	€ 1,000,000	€ 1,000,000
Minimum royalty payment				$ 55,000

Amount of (increase) decrease in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration